Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence.

Adv Hematol · 2015 · PMC4553175 · PMID 26351456

Europe PMC DOI

hedged sentence

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

an unfavorable trendP = 0.10so close (0.05 < p ≤ 0.1)

In the intention-to-treat analysis, there was a trend favoring edoxaban 60 mg versus warfarin (HR: 0.87 (97.5% CI: 0.73–1.04); P = 0.08) and an unfavorable trend with edoxaban 30 mg versus warfarin (HR: 1.13 (97.5% CI: 0.96–1.34); P = 0.10).

also in 104 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.